Citigroup’s Aurinia Pharmaceuticals AUPH Stock Holding History

Citigroup’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$424K	–	6079
2025 Q2	$424K	Buy	+50,000	New	+$401K	﹤0.01%	3728
2025 Q1	–	Sell	-50,000	Closed	-$449K	–	5573
2024 Q4	$449K	Buy	50,000 +30,000	+150%	+$245K	﹤0.01%	3905
2024 Q3	$147K	Sell	20,000 -29,900	-60%	-$185K	﹤0.01%	4567
2024 Q2	$285K	Hold	49,900	–	–	﹤0.01%	3709
2024 Q1	$250K	Buy	+49,900	New	+$339K	﹤0.01%	3905
2023 Q4	–	Sell	-40,000	Closed	-$311K	–	5695
2023 Q3	$311K	Sell	40,000 -9,900	-20%	-$96.8K	﹤0.01%	3398
2023 Q2	$483K	Buy	+49,900	New	+$518K	﹤0.01%	3404

Other funds holding AUPH

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Cookson Peirce & Co Pittsburgh, Pennsylvania $2.77B AUM 64.09% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Citigroup's AUPH Position: Q3 2026 in Review

Citigroup reduced its Aurinia Pharmaceuticals (AUPH) stake by 68% in Q3 2026, selling an estimated $761K and leaving 22,175 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #3938.

Citigroup first reported a position in AUPH in Q4 2014 and has held it in 42 quarters since. The position peaked at $17.6M in Q4 2021. 86 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

Citigroup held 22,175 shares of Aurinia Pharmaceuticals worth $359K as of Q3 2026.
Citigroup sold 47,683 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $761K.
Aurinia Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3938 holding.
Citigroup first reported a position in Aurinia Pharmaceuticals in Q4 2014 and has held it in 42 quarters since.
Citigroup's Aurinia Pharmaceuticals position peaked at $17.6M in Q4 2021.
86 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.